Correlation between serum interleukin-1 receptor antagonist and disease severity in patients with HBV-related liver failure

Lai JingLan; Liu YuMing; Lin Chun; Sun Fang; Zhou Rui; Lin Yong; Lin YuanBao

doi:10.3969/j.issn.1001-5256.2016.05.015

Issue 5

May 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(5): 890-893

PDF( 1619 KB)

Correlation between serum interleukin-1 receptor antagonist and disease severity in patients with HBV-related liver failure

DOI: 10.3969/j.issn.1001-5256.2016.05.015

Department of Hepatology, Fuzhou Infectious Disease Hospital & Mengchao Hepatobiliary Hospital of Fujian Medical University

Research funding:

Published Date: 2016-05-20

Abstract

Abstract

Objective To investigate the correlation between serum interleukin- 1 receptor antagonist( IL- 1Ra) level and disease severity in patients with acute- on- chronic hepatitis B liver failure( HBV- ACLF). Methods A total of 31 patients with HBV- ACLF who visited Fuzhou Infectious Disease Hospital from October 2013 to January 2015 were enrolled as study subjects. Another 28 patients with acute hepatitis B( AHB) and 30 patients with chronic hepatitis B( CHB) were enrolled as controls. The Q- Plex was used to measure the peripheral blood concentrations of cytokines including IL- 1Ra,interleukin- 1β( IL- 1β),interleukin- 6( IL- 6),interleukin- 4,interleukin- 10,tumor necrosis factorα( TNFα),and interferonγ. Liver function and coagulation function were examined for each group,and the correlations of concentrations of serum cytokines including IL- 1Ra with Model for End- Stage Liver Disease( MELD) score and HBV DNA were analyzed. The Kruskal- Wallis H test was used for comparison of continuous data between multiple groups,and the Mann- Whitney U test was used for comparison between any two groups; the chi- square test was used for comparison of categorical data between groups. The Spearman rank correlation was used for correlation analysis. Results The IL- 1Ra level and IL- 1Ra / IL- 1β ratio showed significant differences between the three groups( all P < 0. 05),and the HBV- ACLF group had a significantly higher IL- 1Ra level than the CHB group and the AHB group [186. 46( 162. 68-512. 90) pg/ml vs 70. 47( 47. 07-92. 47) pg/ml,Z =6. 300,P <0. 001; 186. 46( 162. 68-512. 90) pg/ml vs 143. 69( 117. 75-208. 54) pg / ml,Z = 2. 505,P = 0. 012]. The HBV- ACLF group had a significantly lower IL- 1Ra / IL- 1β ratio than the AHB group[2. 92( 2. 20- 4. 74) vs 4. 54( 2. 75- 6. 05),Z = 1. 966,P = 0. 048],but a significantly higher IL- 1Ra/IL- 1β ratio than the CHB group [2. 92( 2. 20- 4. 74) vs 2. 49( 1. 50- 2. 50),Z = 2. 682,P < 0. 001]. The HBV- ACLF group had significantly higher IL- 1β,IL- 6,and TNFα levels than the other two groups( all P < 0. 01). Serum IL- 1Ra level was negatively correlated with total bilirubin( TBil) and MELD score( r =- 0. 506 and- 0. 818,both P < 0. 01) but was positively correlated with prothrombin activity( PTA)( r =0. 475,P = 0. 007). Conclusion IL- 1Ra is negatively correlated with TBil and MELD score and positively correlated with PTA,which are the indicators for the severity of HBV- ACLF. IL- 1Ra may play an important role in the pathogenesis of HBV- ACLF.
- liver failure,
- hepatitis B,chronic,
- interleukin-1

FullText(HTML)

References(14)

References

[1]JALAN R,YURDAYDIN C,BAJAJ JS,et al.Toward an improved definition of acute-on-chronic liver failure[J].Gastroenterology,2014,147(1):4-10.

[2]LIU H,CHEN G,GAN XM.Research advances in new approaches to treatment of acute-on-chronic liver failure[J].J Clin Hepatol,2015,31(9):1496-1500.(in Chinese).刘洪,陈刚,甘雪梅.慢加急性肝衰竭治疗的新技术及其研究进展[J].临床肝胆病杂志,2015,31(9):1496-1500.

[3]LIU Q.Role of cytokines in the pathophysiology of acute-on-chronic liver failure[J].Blood Purification,2009,28(4):331-341.

[4]SARIN SK,KEDARISETTY CK,ABBAS Z,et al.Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL)2014[J].Hepatol Int,2014,8(4):453-471.

[5]National Clinical Guideline Centre(UK).Hepatitis B(chronic):diagnosis and management of chronic hepatitis b in children,young people and adults[EB/OL].NICE Clinical Guidelines(No 165)[2013-06].http://www.ncbi.nlm.nih.gov/pubmed/25473721

[6]WANG DW,YIN YM,YAO YM.Advances in the management of acute liver failure[J].World J Gastroenterol,2013,19(41):7069-7077.

[7]BODE JG,ALBRECHT U,HAUSSINGER D,et al.Hepatic acute phase proteins—regulation by IL-6-and IL-1-type cytokines involving STAT3 and its crosstalk with NF-kappaB-dependent signaling[J].Eur J Cell Biol,2012,91(6-7):496-505.

[8]SHI XL,ZHU W,TAN JJ,et al.Effect evaluation of interleukin-1 receptor antagonist nanoparticles for mesenchymal stem cell transplantation[J].World J Gastroenterol,2013,19(12):1984-1991.

[9]MOLL M,KUEMMERLE-DESCHNER JB.Inflammasome and cytokine blocking strategies in autoinflammatory disorders[J].Clin Immunol,2013,147(3):242-275.

[10]HOPE S,UELAND T,STEEN NE,et al.Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder[J].Schizophrenia research,2013,145(1-3):36-42.

[11]ZHENG YB,ZHANG XH,HUANG ZL,et al.Amniotic-fluid-derived mesenchymal stem cells overexpressing interleukin-1 receptor antagonist improve fulminant hepatic failure[J].PLoS One,2012,7(7):e41392.

[12]SGROI A,GONELLE-GISPERT C,MOREL P,et al.Interleukin-1 receptor antagonist modulates the early phase of liver regeneration after partial hepatectomy in mice[J].PLoS One,2011,6(9):e25442.

[13]DINARELLO CA.Immunological and inflammatory functions of the interleukin-1 family[J].Annu Rev Immunol,2009,27:519-550.

[14]HU J,YAN D,GAO J,et al.rh IL-1Ra reduces hepatocellular apoptosis in mice with acetaminophen-induced acute liver failure[J].Lab Invest,2010,90(12):1737-1746.

Relative Articles

[1]	Zexin HU, Jintao HUANG, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Current status and prospects of transarterial chemoembolization and its combined regimens in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(1): 175-180. doi: 10.12449/JCH240129
[2]	Wencong DAI, Mengya ZANG, Guosheng YUAN, Qi LI, Rong LI, Wenli LI, Shuyu DONG, Jinzhang CHEN. Efficacy of hepatic arterial infusion chemotherapy and its multimodality therapeutic regimens in treatment of patients with advanced hepatocellular carcinoma and related prognostic factors[J]. Journal of Clinical Hepatology, 2023, 39(7): 1592-1599. doi: 10.3969/j.issn.1001-5256.2023.07.013
[3]	Xiufeng LIU, Jue ZHANG, Lin YAO, Chaoxu YANG. Advances in targeted therapy combined with immunotherapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 992-997. doi: 10.3969/j.issn.1001-5256.2022.05.004
[4]	Sirou LI, Yuanlong ZHOU, Keliang LIU, Zhibo LIANG, Jinghua LI. Conversion therapy for massive hepatocellular carcinoma: A case report[J]. Journal of Clinical Hepatology, 2022, 38(7): 1612-1615. doi: 10.3969/j.issn.1001-5256.2022.07.028
[5]	Kailing XIE, Feng XU. Mechanism of action of Huaier granules in treatment of hepatocellular carcinoma and advances in its clinical application[J]. Journal of Clinical Hepatology, 2022, 38(3): 676-681. doi: 10.3969/j.issn.1001-5256.2022.03.038
[6]	Mengkui HAN, Jin LI, Xiaohua YANG. Function and regulatory mechanism of T lymphocytes in tumor immune microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2621-2626. doi: 10.3969/j.issn.1001-5256.2022.11.037
[7]	Zhiyuan HOU, Yuan LIU, Chaoran YANG, Jisen ZHAO, Shujie CHENG. Current research status and prospect of circulating tumor DNA in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2616-2620. doi: 10.3969/j.issn.1001-5256.2022.11.036
[8]	Zhiyuan YU, Shiyu YANG, Jiaqi LI, Yan SUN. Current developmental status of non-surgical treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1205-1207. doi: 10.3969/j.issn.1001-5256.2021.05.048
[9]	Tianle GONG, Ping YUE, Jun YAN, Xun LI. Adjuvant therapies after surgery for hepatocellular carcinoma with microvascular invasion[J]. Journal of Clinical Hepatology, 2021, 37(3): 685-688. doi: 10.3969/j.issn.1001-5256.2021.03.037
[10]	Guoxiang CHEN, Mo ZHOU, Sheng CHEN, Yuan WANG, Yuanlong ZHOU, Jihong YANG. Mechanism of action of non-coding RNA in sorafenib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(3): 699-703. doi: 10.3969/j.issn.1001-5256.2021.03.040
[11]	Shisi LI, Zhitang GUO, Zhangbin CHEN, Yishan TENG. Research advances in systemic therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(12): 2943-2946. doi: 10.3969/j.issn.1001-5256.2021.12.044
[12]	Yanmei ZOU, Xianglin YUAN. Application value of immunotherapy in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1758-1760. doi: 10.3969/j.issn.1001-5256.2021.08.004
[13]	Ningning ZHANG, Wei LU. Targeted therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1753-1757. doi: 10.3969/j.issn.1001-5256.2021.08.003
[14]	Wang XiaoYun, Li LinFeng, Guo Quan, Ceng YiLan, Li HaiYang, Du YingRong, Chen Gang, Liang YueDong, Lu YinYing. Development and enlightenment of intelligentized diagnostic and therapeutic mode for hepatobiliary tumors[J]. Journal of Clinical Hepatology, 2019, 35(10): 2360-2364. doi: 10.3969/j.issn.1001-5256.2019.10.051
[15]	Shang ZhiYin, Yang JingMao, Chen LiPing, Liu Min, Cheng Kai, Li YaoHua, Ai YingChun, Cheng JiLin. Changes in gastrointestinal structure and function caused by cirrhotic portal hypertension and related clinical manifestations[J]. Journal of Clinical Hepatology, 2017, 33(2): 354-358. doi: 10.3969/j.issn.1001-5256.2017.02.034
[16]	Xu ZhengGuo, Zhao YongBing, Zheng YuanYu, Liu En, Yang ShiMing. Association between portal vein pressure drop gradient after transjugular intrahepatic portosystemic shunt and clinical prognosis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2016.12.019
[17]	Shi XiaoJu, Lyu GuoYue, Zhang Ping, Du XiaoHong, Wang GuangYi. Postoperative application of multidisciplinary treatment in patients with hepatobiliary and pancreatic malignancies[J]. Journal of Clinical Hepatology, 2015, 31(11): 1886-1888. doi: 10.3969/j.issn.1001-5256.2015.11.028
[18]	Society of Liver Cancer, Guangdong Provincial Anti-cancer Association. Strategy and method of multi-disciplinary comprehensive treatment of liver cancer-consensus of experts in Guangdong, China (2)[J]. Journal of Clinical Hepatology, 2014, 30(11): 1116-1119. doi: 10.3969/j.issn.1001-5256.2014.11.005
[19]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[20]	Wang JiYao. Importance of detecting portal hypertension in liver cirrhosis patients: theory, research tools, and clinical applications[J]. Journal of Clinical Hepatology, 2012, 28(9): 642-643.

Supplements(0)

Cited By

Cited by

Periodical cited type(20)

1.	秦鹏，李树森，刘皓，吴广迎. 胃冠状静脉栓塞术在门脉高压性上消化道出血经颈静脉肝内门腔静脉分流术患者中的临床疗效. 血管与腔内血管外科杂志. 2022(09): 1130-1134 .
2.	高绍，王宏亮，聂春晖，张岳林，周坦洋，余子牛，杨月，孙军辉. 对比TIPS联合胃冠状静脉栓塞术与单独TIPS治疗肝硬化门静脉高压伴上消化道出血的中远期疗效：Meta分析. 中国介入影像与治疗学. 2022(11): 673-677 .
3.	张大维，吴东辉，孙兴安. TIPS对肝硬化并发上消化道出血患者近期肝肾功能和远期疗效的影响. 当代医学. 2021(35): 129-130 .
4.	林纲毅，马洺远，蔡宗洋. 超声引导下门静脉穿刺导引经颈静脉肝内门体分流术联合曲张静脉栓塞治疗食管胃底静脉曲张破裂出血的临床效果. 中国当代医药. 2020(07): 113-116 .
5.	王宁，林芳明，吕明. TIPS联合GCVE用于门静脉高压并发上消化道大出血的应用价值. 肝脏. 2020(09): 952-954 .
6.	韩志强. 肝硬化上消化道出血37例外科临床治疗效果观察. 世界最新医学信息文摘. 2019(05): 95+102 .
7.	张明礼. PTVE联合PSE治疗肝硬化门脉高压并上消化道出血的观察. 实用中西医结合临床. 2019(05): 24-26 .
8.	孙允涛. 肝硬化门静脉高压并发上消化道出血的相关危险因素分析. 中国民康医学. 2019(10): 81-83 .
9.	孙巧玉，赖雪珍，河源媛. 门脉高压合并上消化道出血采用PTVE联合PSE手术的效果分析. 现代消化及介入诊疗. 2019(08): 837-841+846 .
10.	杨荣焕. TIPS和PTVE介入方法治疗肝硬化门静脉高压引起的上消化道出血的优劣差异. 黑龙江医学. 2019(09): 1012-1013+1016 .
11.	武和平. 不同介入途径胃冠状静脉栓塞术治疗肝硬化门静脉高压出血的临床疗效观察. 现代消化及介入诊疗. 2018(02): 208-210 .
12.	李广忠. 分析肝硬化门脉高压症下食管静脉曲张破裂出血的危险因素. 智慧健康. 2018(07): 91-92+126 .
13.	李贤圣，董勤勇，张乐，夏侨，贺军. 经颈静脉门静脉分流术介入治疗门静脉高压引起上消化道出血的疗效分析. 浙江创伤外科. 2018(02): 272-273 .
14.	赵晓飞，林栋栋，李宁，臧运金，郭庆良，武聚山. 门静脉高压患者脾切断流术后曲张静脉再出血的危险因素分析. 临床肝胆病杂志. 2018(10): 2182-2185 . 本站查看
15.	吴笋. 经颈静脉肝内门体静脉分流术加胃冠状静脉栓塞术治疗门脉高压症初探. 现代医用影像学. 2018(05): 1522-1523+1528 .
16.	田广俊，池晓玲，常钢，孟凡喆，曹敏玲，黎英贤，徐浩祥，梁宏才，赵朋涛，吴晓菊，萧焕明. 中药灌肠防治TIPS治疗肝硬化门静脉高压伴上消化道出血术后肝性脑病临床观察. 新中医. 2018(12): 87-91 .
17.	樊春燕，叶晓丽，戴晓婷，吴宇清. 肝硬化门静脉高压并发上消化道出血的相关性分析研究. 血管与腔内血管外科杂志. 2018(05): 381-385 .
18.	彭虹. 肝硬化门静脉高压并发上消化道出血的相关危险因素分析. 中国继续医学教育. 2017(31): 58-59 .
19.	张志勇. 不同手术方案治疗肝硬化门脉高压症的临床对比. 临床医药文献电子杂志. 2017(46): 8924-8925 .
20.	向平，张川，张亮科，唐瑞强，叶继彬. 1例上消化道出血病人护理体会. 世界最新医学信息文摘. 2016(14): 247 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2332) PDF downloads(461)

Correlation between serum interleukin-1 receptor antagonist and disease severity in patients with HBV-related liver failure

DOI: 10.3969/j.issn.1001-5256.2016.05.015